Curetis Announces Participation in Several Investor and Industry Conferences in Q2-2016
Amsterdam, the Netherlands and Holzgerlingen, Germany, March 24, 2016 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced its participation in several major industry conferences in the second quarter of 2016. The respective investor presentations will be made available on the company’s website.
26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9 – 12, 2016, in Amsterdam, The Netherlands: scientific meeting
Morgan Stanley Panel discussion and Meeting on Infectious Disease Diagnostics, April 14, 2016 in New York, NY, USA
Bio€quity Europe 2016, May 10-11, 2016 in Copenhagen, Denmark: management presentation
35th Annual Conference of the Austrian Society for Hygiene, Microbiology and Prevention (ÖGHMP), May 30-June 2nd in Zell am See, Austria: scientific meeting
Swiss MedLab, June 13-16, Berne, Switzerland: scientific meeting
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
According to §§ 190 ff. German Reorganization Act (UmwG) and by way of enrolment in the commercial register at district court Stuttgart on March 15, 2016 Curetis plc (AG) changed its legal form into Curetis Ltd. (GmbH).
71088 Holzgerlingen, Germany
International Media & Investor Inquiries
Dr. Ludger Wess / Ines-Regina Buth
U.S. Media & Investor Inquiries
The Ruth Group
Contact // Kontakt akampion Newswire:
Dr. Ludger Wess
Managing Partner, akampion
Managing Partner, akampion